Literature DB >> 19853692

Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative.

Ezra A Amsterdam1, Eric D Peterson, Fang-Shu Ou, L Kristin Newby, Charles V Pollack, W Brian Gibler, E Magnus Ohman, Matthew T Roe.   

Abstract

BACKGROUND: Prior studies have demonstrated differences in adherence to non-ST-segment elevation acute coronary syndromes (NSTE ACS) guidelines-recommended therapies among patients managed conservatively without cardiac catheterization compared with those managed invasively. We evaluated the degree of yearly change in use of guidelines-recommended therapies for patients with NSTE ACS in CRUSADE stratified by use of cardiac catheterization and revascularization procedures.
METHODS: We analyzed data from 138,714 high-risk patients with NSTE ACS treated at 547 hospitals during the first 4 years of the CRUSADE initiative. Patients were categorized as no cardiac catheterization (29% of the total population), cardiac catheterization without revascularization (21%), percutaneous coronary intervention (40%), and coronary artery bypass graft surgery (11%). Composite guidelines adherence scores were used to compare yearly changes in use of guidelines-recommended therapies among the groups.
RESULTS: Although guidelines adherence improved in all 4 groups each year and was consistently highest in the percutaneous coronary intervention group, the adjusted yearly increase in the use of acute guidelines-recommended medications was highest in the no cardiac catheterization group, and the adjusted yearly increase in the use of discharge medications was highest in the coronary artery bypass graft surgery group.
CONCLUSIONS: Improvements in the use of guidelines-recommended therapies were seen among all patients with NSTE ACS in CRUSADE over a 4-year period regardless of management strategy, and the trajectory of improvement in acute care was greatest in patients managed conservatively.

Entities:  

Mesh:

Year:  2009        PMID: 19853692     DOI: 10.1016/j.ahj.2009.09.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

1.  Impact of myocardial revascularization on long-term outcomes in a nationwide cohort of first acute myocardial infarction survivors.

Authors:  Leonardo De Luca; Paola D'Errigo; Stefano Rosato; Gian Francesco Mureddu; Gabriella Badoni; Fulvia Seccareccia; Giovanni Baglio
Journal:  Eur Heart J Suppl       Date:  2022-05-18       Impact factor: 1.624

2.  ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.

Authors:  Deborah B Diercks; Michael C Kontos; Judd E Hollander; Bryn E Mumma; DaJuanicia N Holmes; Stephen Wiviott; Jorge F Saucedo; James A de Lemos
Journal:  Am J Emerg Med       Date:  2013-05-20       Impact factor: 2.469

3.  Baseline characteristics, management practices, and in-hospital outcomes of patients with acute coronary syndromes: Results of the Saudi project for assessment of coronary events (SPACE) registry.

Authors:  Khalid F Alhabib; Ahmad Hersi; Hussam Alfaleh; Khalid Alnemer; Shukri Alsaif; Amir Taraben; Tarek Kashour; Anas Bakheet; Ayed Al Qarni; Tariq Soomro; Asif Malik; Waqar H Ahmed; Ahmed M Abuosa; Modaser A Butt; Mushabab A Almurayeh; Abdulaziz Al Zaidi; Gamal A Hussein; Mohammed A Balghith; Tareg Abu-Ghazala
Journal:  J Saudi Heart Assoc       Date:  2011-06-01

4.  Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes.

Authors:  Hélder Dores; Carlos Aguiar; Jorge Ferreira; Jorge Mimoso; Sílvia Monteiro; Filipe Seixo; José Ferreira Santos
Journal:  Cardiovasc Diagn Ther       Date:  2014-02

5.  Economic burden of illness of acute coronary syndromes: medical and productivity costs.

Authors:  Zhenxiang Zhao; Melissa Winget
Journal:  BMC Health Serv Res       Date:  2011-02-14       Impact factor: 2.655

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Stefan K James; Matthew T Roe; Christopher P Cannon; Jan H Cornel; Jay Horrow; Steen Husted; Hugo Katus; Joao Morais; Ph Gabriel Steg; Robert F Storey; Susanna Stevens; Lars Wallentin; Robert A Harrington
Journal:  BMJ       Date:  2011-06-17

7.  Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE).

Authors:  Leonardo De Luca; Furio Colivicchi; Michele Massimo Gulizia; Francesco Rocco Pugliese; Maria Pia Ruggieri; Giuseppe Musumeci; Gian Alfonso Cibinel; Francesco Romeo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

8.  Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study.

Authors:  Cengiz Özcan; Anna Deleskog; Anne-Marie Schjerning Olsen; Helene Nordahl Christensen; Morten Lock Hansen; Gunnar Hilmar Gislason
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

9.  Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.

Authors:  Daniel Lindholm; Christoph Varenhorst; Christopher P Cannon; Robert A Harrington; Anders Himmelmann; Juan Maya; Steen Husted; Philippe Gabriel Steg; Jan H Cornel; Robert F Storey; Susanna R Stevens; Lars Wallentin; Stefan K James
Journal:  Eur Heart J       Date:  2014-04-11       Impact factor: 29.983

10.  Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study.

Authors:  Fatih Sinan Ertaş; Lale Tokgözoğlu
Journal:  Anatol J Cardiol       Date:  2016-06-29       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.